{"id":2019,"date":"2024-04-11T14:33:50","date_gmt":"2024-04-11T14:33:50","guid":{"rendered":"https:\/\/stoxpo.com\/?p=2019"},"modified":"2024-04-11T14:33:51","modified_gmt":"2024-04-11T14:33:51","slug":"candel-therapeutics-can-2409-receives-fda-orphan-drug-designation-for-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/04\/11\/candel-therapeutics-can-2409-receives-fda-orphan-drug-designation-for-pancreatic-cancer\/","title":{"rendered":"Candel Therapeutics&#8217; CAN-2409 Receives FDA Orphan Drug Designation for Pancreatic Cancer"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">Milestone Achievement Enhances Development Efforts for Multimodal Biological Immunotherapy<\/h3>\n\n\n\n<p>Candel Therapeutics (CADL) has achieved a significant milestone in its fight against pancreatic cancer with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation to CAN-2409, the company&#8217;s advanced multimodal biological immunotherapy candidate.<\/p>\n\n\n\n<p>CAN-2409 has demonstrated promising results in a phase 2 randomized clinical trial for borderline resectable pancreatic cancer, showing a notable improvement in median overall survival when combined with standard of care. The FDA&#8217;s recognition through Orphan Drug Designation underscores the therapeutic potential of CAN-2409 in addressing the unmet medical needs of patients battling this challenging disease.<\/p>\n\n\n\n<p>&#8220;We are thrilled by the FDA&#8217;s decision to grant Orphan Drug Designation to CAN-2409, further validating our commitment to advancing innovative therapies for pancreatic cancer,&#8221; stated Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel Therapeutics. &#8220;This designation, coupled with Fast Track Designation, underscores the urgency and importance of our mission to redefine the treatment landscape for pancreatic cancer.&#8221;<\/p>\n\n\n\n<p>Orphan Drug Designation provides Candel with valuable financial incentives and potential marketing exclusivity, empowering the company to accelerate the development of CAN-2409 and bring hope to patients fighting this rare and devastating form of cancer. With ongoing positive clinical trial results, Candel remains dedicated to leveraging CAN-2409&#8217;s multimodal approach to combat pancreatic cancer and other challenging-to-treat cancers.<\/p>\n\n\n\n<p>Read original press release:<a href=\"https:\/\/finance.yahoo.com\/news\/candel-therapeutics-receives-fda-orphan-130000386.html\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">here<\/mark><\/a><\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/04\/11\/rallybio-collaborates-with-johnson-johnson-to-tackle-rare-disease-fnait\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Rallybio Collaborates with Johnson &amp; Johnson to Tackle Rare Disease FNAIT<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Milestone Achievement Enhances Development Efforts for Multimodal Biological Immunotherapy Candel Therapeutics (CADL) has achieved a significant milestone in its fight against pancreatic cancer with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation to CAN-2409, the company&#8217;s advanced multimodal biological immunotherapy candidate. CAN-2409 has demonstrated promising results in a phase 2 randomized clinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1429,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[308,358],"tags":[],"coauthors":[453],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2019"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=2019"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2019\/revisions"}],"predecessor-version":[{"id":2021,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2019\/revisions\/2021"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1429"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=2019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=2019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=2019"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=2019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}